November 11, 2025
Calendar
10:00am - 11:00am
(GMT-05:00)
In this live panel discussion, five IQVIA experts will examine the most critical safety and regulatory compliance shifts for 2026. Attendees will gain insights into AI’s real impact on regulatory operations and pharmacovigilance, the evolving stewardship role of medical information (MI) and how target product profiles (TPPs) can drive faster, smarter development decisions.
Attendees will leave with clear, actionable steps that can be applied immediately, including how to operationalize human-in-the-loop AI without compromising compliance, what to document and validate under the latest FDA guidance, how Local Qualified Persons for Pharmacovigilance (LQPPVs) should oversee vendor algorithms, the transparency standards MI teams must adopt and how TPPs can help pivot confidently amid uncertainty.
As regulatory frameworks continue to evolve, the conversation has shifted from “if” to “how” AI can augment the work of safety and regulatory professionals. For success in 2026, organizations should learn how to integrate AI transparently, maintain robust governance and unify decisions under shared strategic goals.
Register for this webinar to turn complexity into clarity and to learn how safety and regulatory compliance priorities are expected to shift through 2026.
Attendees will:
Speakers:
Michelle Gyzen, Senior Director, Strategic Regulatory Solutions; Head of Regulatory Services Innovation & Technology, IQVIA
Archana Hegde, Senior Director, PV Systems & Innovations, Lifecycle Safety, IQVIA
Ian Fisher, Head of Development Analytics, Regulatory Affairs and Drug Development Solutions, IQVIA
Louise Molloy, Associate Director Medical Information & Pharmacovigilance, IQVIA
Ana Pedro Jesuíno, Associate Director of Marketed Product Safety, IQVIA
For more information and to register, click here.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
.svg){kind=icon}
